I want to start with the part most articles about this leave out: the people taking fenbendazole are not being stupid, and the mechanism they are citing is real.
That matters, because if you have been told this is a foolish thing that only gullible people do, and you have read even a little of the actual science, you will correctly conclude that whoever told you that had not read it either. And then you will stop listening to them about anything.
So let me go through what is actually known, including the parts that support the interest, and then the parts that should genuinely worry you.
What fenbendazole is, and why anyone thought of this
Fenbendazole is a benzimidazole anthelmintic, a deworming drug approved for veterinary use. It is cheap, it has been given to animals for decades, and it is easy to obtain.
The interest in it for cancer is not invented from nothing.
In a 2018 paper in Scientific Reports, Dogra and colleagues showed that fenbendazole has moderate affinity for mammalian tubulin and kills human cancer cells in culture at micromolar concentrations. It caused mitochondrial translocation of p53. It inhibited glucose uptake, the GLUT transporters, and hexokinase II, a key glycolytic enzyme. And when mice carrying human tumor xenografts were fed the drug orally, it blocked tumor growth.
Hold on to one detail about those mice, because it comes back later. They were athymic nude mice, bred without a working immune system.
Now connect that to the last article in this series.
Fenbendazole disrupts microtubules. So does vincristine. The FDA-approved labeling for vincristine describes its mechanism as the inhibition of microtubule formation in the mitotic spindle, arresting dividing cells at metaphase. Microtubule-targeting agents are not a fringe theory about cancer. They are one of the central drug classes in oncology.
Two cautions, and I want to get both of them right, because this is the sentence everything else in the article rests on.
The first is that paclitaxel is usually swept into this comparison and it does not belong there. Its FDA-approved labeling says paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes them by preventing depolymerization. It pushes in the opposite direction. Fenbendazole is a destabilizer. Vincristine is the correct comparison, and it is the only one.
The second is that the argument works at the level of the target, not the family. Drugs that target microtubules have produced real chemotherapy. Benzimidazole dewormers, which is the family fenbendazole actually belongs to, have not produced an approved cancer drug. Sliding from the first statement to the second is how a reasonable idea turns into a false one.
A 2022 review in Current Issues in Molecular Biology, by Sultana and colleagues, describes the mechanism for fenbendazole itself in the same terms: inhibition of microtubule polymerization, and blockade of glucose uptake.
So when somebody tells you there is a plausible reason to think a dewormer might do something to cancer, they are right. That is not the problem.
Where the evidence stops
Here is the entire problem in one sentence: every result I just described is from cells in a dish or from mice.
And the mouse record is not one-sided, which is the part that almost never gets quoted.
In 2008, a group at Johns Hopkins reported that neither vitamin supplementation alone nor fenbendazole alone altered tumor growth compared with controls. Only the combination of the two inhibited growth, and the authors called the mechanism unknown. At Yale, in the Department of Therapeutic Radiology, fenbendazole was tested twice. In 2012 the medicated diet did not alter tumor growth, invasion, or metastasis. In 2013, fenbendazole in maximally intensive regimens did not alter tumor growth and did not add to the effects of radiation. The published conclusion, in their words, is that these studies provided no evidence that fenbendazole would have value in cancer therapy, though they added that the general class of compounds merits further investigation.
Now the detail I asked you to hold on to. The 2018 result that started all of this was obtained in mice bred without an immune system, and so was the 2008 work at Hopkins.
In 2023, a group at Jeju National University gave fenbendazole to mice with intact immune systems carrying lymphoma. Tumor growth was comparable to control. The treated animals lost weight rapidly. The treated tumors showed more mitotic figures, the tumor cells carried more PD-L1, and the proportion of immunosuppressive macrophages inside the tumor went up. At a higher dose, the treated tumors weighed more than the tumors in untreated animals. The authors close by writing that caution should be exercised in the clinical use of fenbendazole because of the potential risks associated with its anticancer effects.
I am putting that in because it cuts against the sympathetic framing I opened with, and you should have it anyway. A drug that shrinks a tumor in an animal with no immune system, and does not in an animal that has one, has not been shown to work in an intact body. The immune system is not a detail in cancer. It is frequently the thing doing the work.
There is no completed human trial of fenbendazole for cancer. In August 2026, ClinicalTrials.gov, the United States government’s trials register, and the World Health Organization’s international registry were both searched, and none was found.
ClinicalTrials.gov holds zero fenbendazole studies. The handful of hits a search returns are other things entirely: trials of oxfendazole, a separately registered drug that happens to be fenbendazole’s metabolite, and string matches on the brand name Safe-Guard, one of which is a firearm safety counseling study.
The WHO registry returns exactly one record in the world, and I am going to name it, because sooner or later somebody will produce it as proof that a trial exists. It is ACTRN12623001164684, an uncontrolled, non-randomized, single-group case series at one private clinic in Queensland, Australia, paid for by the patients enrolled in it. Fenbendazole is item thirteen of a nineteen-item protocol given all together. The primary outcome is a circulating tumor cell count, not survival and not tumor response. No results have been posted.
That study cannot answer the question, for three separate reasons: there is no control arm, nineteen agents are given at once, and the endpoint is a surrogate. So what exists is a mechanism, a split animal record, one registered case series that cannot isolate the drug, and a very large number of internet posts.
I want to be precise about what that does and does not mean. It does not mean fenbendazole has been proven not to work. It means nobody knows, and the reason nobody knows is that the study capable of producing an inconvenient answer has never been run.
The history of oncology is full of compounds that looked exactly this promising in mice and did nothing in people. That is the ordinary outcome, not the exception.
The part that should worry you
While the efficacy question sits unanswered, the harm question has started producing answers. The published human record of people taking fenbendazole for cancer runs from 2021 to 2026, and it is a record of liver injury.
It starts with an 80-year-old woman in Nagoya with advanced non-small cell lung cancer, on pembrolizumab, described by Yamaguchi and colleagues in Case Reports in Oncology in 2021. She developed severe liver injury after a month of fenbendazole, which she had taken solely on the basis of social media reports. The history came out in an interview with her and her family. Her liver dysfunction resolved on its own once she stopped. And the authors record, plainly, that she did not experience tumor shrinkage.
That case is five years old, and it already contains both of the things this article is about: a patient on immunotherapy, and a medication history that surfaced through the family.
In 2024, in the ACG Case Reports Journal, a team at the University of Louisville described what they call the first histologically confirmed case of severe drug-induced liver injury, hepatocellular pattern, from self-administered fenbendazole, in a 67-year-old woman who presented with two weeks of jaundice. Her liver function tests normalized three months after she stopped.
In 2025, a group at UT Southwestern reported a woman with metastatic breast cancer who came in for routine pre-chemotherapy labs with a badly abnormal liver panel and no symptoms at all. Her son later disclosed that she had been taking veterinary-grade fenbendazole. She was discharged with counseling to stop it and with outpatient monitoring. One caveat that belongs in the text rather than a footnote: this one is a conference abstract published in a supplement of the American Journal of Gastroenterology, not a peer-reviewed case report, and the two are not the same thing.
The case published in World Journal of Clinical Cases in 2026 by Krishnan and colleagues is the one I would most want a patient to read. A 47-year-old woman with metastatic colon cancer, receiving nivolumab and relatlimab, developed severe hepatocellular liver injury after taking fenbendazole she had started following a consultation with a holistic healer.
Her liver injury looked like immunotherapy-induced hepatitis.
Think about what that means. Immune checkpoint inhibitors can cause immune-mediated hepatitis, and the standard response is to stop the immunotherapy and start immunosuppression. Her team’s initial concern was exactly that. What the authors write is that misdiagnosing it early could have led to unnecessary corticosteroid treatment, an unnecessary liver biopsy, and premature discontinuation of the immunotherapy. That is their conditional and I am keeping it as they wrote it. Because the medication history was re-verified in detail during the hepatology consultation, and a structured causality assessment was run, fenbendazole was identified as the probable cause, steroids were withheld, the biopsy was deferred, and she resumed her immunotherapy a month after discharge.
In Cureus in 2026, a 65-year-old man with prostate cancer arrived jaundiced with hepatocellular injury after taking veterinary fenbendazole together with ivermectin, on the advice of online cancer support groups. An extensive workup ruled out viral, autoimmune and biliary causes, and structured causality assessment scored it highly probable. Two drugs were taken together in that case, so it cannot be laid at fenbendazole’s door alone, and I am not going to present it as though it could.
The sixth report, in the ACG Case Reports Journal in 2026, is a fenbendazole liver injury in a patient who was simultaneously taking a second product marketed as a liver protectant. It did not prevent the injury.
All six recovered after stopping. That is the good news and it is worth stating clearly. But all six also lost time and underwent workups they did not need, and in one of them the injury landed in the middle of a decision about whether to continue immunotherapy.
The argument that actually matters
Notice that not one of those cases is a story about a supplement being useless.
They are stories about a substance colliding with cancer care that was already underway. That is the point I keep returning to across this series, and fenbendazole may be its clearest example. The risk is not that you waste money. The risk is that you develop a liver injury that looks like a treatment complication, at the exact moment your team is deciding whether to continue the thing keeping you alive.
And the thread running through these cases is the same: the team did not know. In one, it was the patient’s son who told the team. In another, the history came out only in an interview with the patient and her family. In a third, it surfaced because a hepatology consult went back through the medications one at a time. If you take nothing else from this, take that. Whatever you are taking, they need to know, and they need to know before it shows up in your bloodwork.
The related drug you will be pointed to
There is a benzimidazole approved for people. Mebendazole is a human antiparasitic drug, and if the mechanism is what interests you, this is where the conversation almost always goes next. So it is worth knowing what is actually there.
Mebendazole has been given to cancer patients in registered trials. Searched in August 2026, the register holds a small set of them in oncology, and they are early and they are small. Two completed phase 1 studies at Johns Hopkins, one in high-grade glioma that enrolled twenty-four patients and one in recurrent pediatric brain tumors that enrolled sixteen. A phase 1 and 2 study in pediatric gliomas that enrolled ten and has been listed as active but not recruiting since 2013. A phase 1 and 2 study in gastrointestinal cancer that was terminated after eleven. A few others still open, including one in colorectal cancer that is not scheduled to reach primary completion until 2028.
Phase 1 studies are dose and safety studies by design. They are not built to show that a drug treats cancer, and no completed trial has established that mebendazole does. It carries no cancer indication from any regulator.
I am including this because you will meet the argument, not because it is an answer. The honest version is that the human-approved relative of this drug is near the beginning of being studied, not near the end, and that is a different thing from a treatment.
What would change my answer
A human trial of fenbendazole. That is all. A phase 1 study to establish a dose and a safety profile in people, then a real efficacy study.
It has not been done. You will usually hear one explanation for that, which is that fenbendazole is off patent and costs almost nothing, so no company can recover the cost of testing it. I find that argument plausible and I am going to flag it as an argument rather than a finding, because I cannot point you to a source that establishes it for this drug, and it sits awkwardly beside the one registered study in the world, which is being paid for by the patients enrolled in it.
What is documented is narrower and harder to argue with. Fenbendazole is not approved by the FDA or the European Medicines Agency for any human use, and as the authors of a 2024 review who are arguing in favor of testing it put it, its pharmacokinetics and safety in humans have yet to be well documented in the medical literature. Nobody has established a human dose. That is not a gap in the marketing. It is a gap in what is known.
But “the trial was never run” and “the drug works” are different statements. The first one is true. The second one is unknown, and taking a veterinary drug at a dose nobody has established is not a way of finding out. It is a way of becoming a case report.
What I would do
If you are taking fenbendazole, or thinking about it, tell your oncology team. Not eventually. Before your next labs. They are not going to throw you out of the clinic, and they need it in the chart to interpret your liver enzymes correctly.
If somebody you love is taking it and has not told anyone, that conversation is worth having. In two of the cases above, the family is how the team found out at all.
This is education, not medical advice. Nothing here is a recommendation to start or stop any treatment. If you are in treatment, decisions belong with your oncology team, and if something is urgent, call them. In an emergency, call 911.
Next Wednesday: what these drugs actually do inside a cell, and why every side effect follows from it.
---
*I wrote two books on nutrition during cancer treatment before I wrote any of these articles, one for patients and one for caregivers, in English and in Spanish.*
References
Sources retrieved and checked in August 2026.
Mechanism and labeling
Paclitaxel Injection, FDA-approved labeling, DailyMed, US Food and Drug Administration.
Vincristine Sulfate Injection, FDA-approved labeling, DailyMed, US Food and Drug Administration.
Panacur (fenbendazole) Suspension, FDA-approved animal labeling, DailyMed, US Food and Drug Administration, revised August 2025.
Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports. 2018;8:11926. doi:10.1038/s41598-018-30158-6
Sultana T, Jan U, Lee H, Lee H, Lee JI. Exceptional repositioning of dog dewormer: fenbendazole fever. Current Issues in Molecular Biology. 2022;44(10):4977-4986. doi:10.3390/cimb44100338
The animal record
Gao P, Dang CV, Watson J. Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. Journal of the American Association for Laboratory Animal Science. 2008;47(6):37-40.
Duan Q, Liu Y, Booth CJ, Rockwell S. Journal of the American Association for Laboratory Animal Science. 2012;51(2):224-230.
Duan Q, Liu Y, Rockwell S. Fenbendazole as a potential anticancer drug. Anticancer Research. 2013;33(2):355-362.
Jung H, Kim SY, Joo HG. Fenbendazole exhibits differential anticancer effects in vitro and in vivo in models of mouse lymphoma. Current Issues in Molecular Biology. 2023;45(11):8925-8938. doi:10.3390/cimb45110560
Registries and the human record
ClinicalTrials.gov, US National Library of Medicine. Searched 9 August 2026.
World Health Organization International Clinical Trials Registry Platform. Searched 9 August 2026. Record ACTRN12623001164684, Australian New Zealand Clinical Trials Registry.
Yamaguchi T, Shimizu J, Oya Y, Horio Y, Hida T. Drug-induced liver injury in a patient with nonsmall cell lung cancer after the self-administration of fenbendazole based on social media information. Case Reports in Oncology. 2021;14(2):886-891. doi:10.1159/000516276
Thakurdesai A, Rivera-Matos L, Nagra N, Busch B, Mais DD, Cave MC. Severe drug-induced liver injury due to self-administration of the veterinary anthelmintic medication, fenbendazole. ACG Case Reports Journal. 2024;11(5):e01354. doi:10.14309/crj.0000000000001354
Chaturvedi M, Saba L, Amroze A, et al. Drug-induced liver injury from off-label fenbendazole use in metastatic breast cancer: a case report. American Journal of Gastroenterology. 2025;120(10S2):S38. Conference abstract, American College of Gastroenterology 2025 Annual Scientific Meeting.
Krishnan A, Lucas K, Maas L, Woreta TA. Differentiating fenbendazole-induced liver injury from immunotherapy hepatitis: the importance of structured causality assessment. World Journal of Clinical Cases. 2026;14(2):116700. doi:10.12998/wjcc.v14.i2.116700
Powderly GE, Hassevoort K, Loy M, Balonier J, Sievers C. Drug-induced liver injury following co-ingestion of veterinary fenbendazole and ivermectin for prostate cancer: a case report. Cureus. 2026;18(5):e108896. doi:10.7759/cureus.108896
Satinsky A, Mayer N, Swanson C, Sasso B. Fenbendazole-associated drug-induced liver injury with concomitant use of tauroursodeoxycholic acid. ACG Case Reports Journal. 2026;13(7):e02222. doi:10.14309/crj.0000000000002222
Nguyen J, Nguyen TQ, Han B, Hoang BX. Oral fenbendazole for cancer therapy in humans and animals. Anticancer Research. 2024;44(9):3725-3735. doi:10.21873/anticanres.17197
Vitae Arete provides nutrition education and does not diagnose, treat, or manage cancer, nor prescribe or manage medication. This article is general information, not individualized medical or nutrition advice, and does not create a dietitian–client relationship. See the full disclaimer.